PDS Biotechnology Corp
NASDAQ:PDSB

Watchlist Manager
PDS Biotechnology Corp Logo
PDS Biotechnology Corp
NASDAQ:PDSB
Watchlist
Price: 0.8533 USD 2.41% Market Closed
Market Cap: 44.7m USD

PDS Biotechnology Corp
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

PDS Biotechnology Corp
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
PDS Biotechnology Corp
NASDAQ:PDSB
Operating Income
-$32.2m
CAGR 3-Years
-3%
CAGR 5-Years
-21%
CAGR 10-Years
-4%
Abbvie Inc
NYSE:ABBV
Operating Income
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$11.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Income
$12.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.5B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$3.9B
CAGR 3-Years
-17%
CAGR 5-Years
4%
CAGR 10-Years
12%
No Stocks Found

PDS Biotechnology Corp
Glance View

Market Cap
40.7m USD
Industry
Biotechnology

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company is headquartered in Florham Park, New Jersey and currently employs 22 full-time employees. The company went IPO on 2015-10-01. The firm is engaged in the developing a pipeline of molecularly targeted immunotherapies. The firm owns the T-cell activating platforms designed to train the immune system to attack and destroy disease; Versamune, for treatments in oncology and Infectimune, for treatments in infectious disease. Infectimune is also designed to promote the induction of disease-specific neutralizing antibodies. Its immuno-oncology product candidates are of potential interest for use as a component of combination product candidates to provide treatments across a range of advanced and/or refractory cancers. The company develops targeted product candidates to treat several cancers, including Human Papillomavirus (HPV) associated cancers, melanoma, colorectal, lung, breast and prostate cancers. Its infectious disease candidates are of potential interest as vaccines to prevent COVID-19 and universal influenza.

PDSB Intrinsic Value
Not Available

See Also

What is PDS Biotechnology Corp's Operating Income?
Operating Income
-32.2m USD

Based on the financial report for Sep 30, 2025, PDS Biotechnology Corp's Operating Income amounts to -32.2m USD.

What is PDS Biotechnology Corp's Operating Income growth rate?
Operating Income CAGR 10Y
-4%

Over the last year, the Operating Income growth was 18%. The average annual Operating Income growth rates for PDS Biotechnology Corp have been -3% over the past three years , -21% over the past five years , and -4% over the past ten years .

Back to Top